# Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

> **NCT05088226** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Peripheral Blood Stem Cell Transplantation

## Interventions

- **DRUG:** Ruxolitinib combined with Chidamide.

## Key facts

- **NCT ID:** NCT05088226
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2030-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088226, "Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05088226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*